Literature DB >> 31216010

Duration and life-stage of antibiotic use and risk of cardiovascular events in women.

Yoriko Heianza1, Yan Zheng2, Wenjie Ma3, Eric B Rimm4,5,6, Christine M Albert7, Frank B Hu4,5,6, Kathryn M Rexrode7,8, JoAnn E Manson5,6,7, Lu Qi1,4,6.   

Abstract

AIMS: Growing data suggest that antibiotic exposure is associated with a long-lasting alteration in gut microbiota, and may be related to subsequent cardiovascular disease (CVD). We investigated associations of life-stage and duration of antibiotic exposure during adulthood with subsequent CVD events. METHODS AND
RESULTS: This study included 36 429 women initially free of CVD and cancer from the Nurses' Health Study. We estimated hazard ratios (HRs) for CVD (a composite endpoint of coronary heart disease or stroke) according to duration of antibiotic use in young (age 20-39), middle (age 40-59), and late (age 60 and older) adulthood. During an average of 7.6 years of follow-up, 1056 participants developed CVD. Women with long-term use of antibiotics (for ≥2 months) in late adulthood had a significantly increased risk of CVD (HR 1.32, 95% confidence interval 1.03-1.70) after adjustment for covariates (such as demographic factors, diet and lifestyle, reasons for antibiotic use, overweight or obesity, disease status, and other medication use), as compared to women who did not use antibiotics in this life-stage. Longer duration of antibiotic use in middle adulthood was also related to higher risk of CVD (P trend = 0.003) after controlling for these covariates. There was no significant relationship between the use in young adulthood and the risk of CVD.
CONCLUSION: In this study which examined the antibiotic use in different life-stages, longer duration of exposure to antibiotics in the middle and older adulthood was related to an increased risk of future CVD events among elderly women at usual risk. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Antibiotics; Cardiovascular disease; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31216010      PMCID: PMC6911167          DOI: 10.1093/eurheartj/ehz231

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  49 in total

Review 1.  Long-term impacts of antibiotic exposure on the human intestinal microbiota.

Authors:  Cecilia Jernberg; Sonja Löfmark; Charlotta Edlund; Janet K Jansson
Journal:  Microbiology (Reading)       Date:  2010-08-12       Impact factor: 2.777

2.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.

Authors:  Janine R Hutson; Hadas D Fischer; Xuesong Wang; Andrea Gruneir; Nick Daneman; Sudeep S Gill; Paula A Rochon; Geoffrey M Anderson
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

Review 4.  Antibiotics and the gut microbiota.

Authors:  Sheetal R Modi; James J Collins; David A Relman
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

5.  Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.

Authors:  Peter J Leary; Ryan J Tedford; David A Bluemke; Michael R Bristow; Susan R Heckbert; Steven M Kawut; Eric V Krieger; Joao A Lima; Carolina S Masri; David D Ralph; Steven Shea; Noel S Weiss; Richard A Kronmal
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

6.  Lack of association between azithromycin and death from cardiovascular causes.

Authors:  Christine M Khosropour; Jeffrey D Capizzi; Sean D Schafer; James B Kent; Julia C Dombrowski; Matthew R Golden
Journal:  N Engl J Med       Date:  2014-05-15       Impact factor: 91.245

7.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

8.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.

Authors:  Mette Charlot; Erik L Grove; Peter Riis Hansen; Jonas B Olesen; Ole Ahlehoff; Christian Selmer; Jesper Lindhardsen; Jan Kyst Madsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  BMJ       Date:  2011-05-11

9.  Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  BMJ       Date:  2014-08-19

10.  Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children.

Authors:  Katri Korpela; Anne Salonen; Lauri J Virta; Riina A Kekkonen; Kristoffer Forslund; Peer Bork; Willem M de Vos
Journal:  Nat Commun       Date:  2016-01-26       Impact factor: 14.919

View more
  8 in total

1.  Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study.

Authors:  Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Circ Res       Date:  2019-12-17       Impact factor: 17.367

Review 2.  Microbiota in cerebrovascular disease: A key player and future therapeutic target.

Authors:  Shuichi Tonomura; Masafumi Ihara; Robert P Friedland
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-20       Impact factor: 6.200

3.  Human Gut Antibiotic Resistome and Progression of Diabetes.

Authors:  Menglei Shuai; Guoqing Zhang; Fang-Fang Zeng; Yuanqing Fu; Xinxiu Liang; Ling Yuan; Fengzhe Xu; Wanglong Gou; Zelei Miao; Zengliang Jiang; Jia-Ting Wang; Lai-Bao Zhuo; Yu-Ming Chen; Feng Ju; Ju-Sheng Zheng
Journal:  Adv Sci (Weinh)       Date:  2022-02-10       Impact factor: 16.806

4.  Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment.

Authors:  Ben Arpad Kappel; Lorenzo De Angelis; Michael Heiser; Marta Ballanti; Robert Stoehr; Claudia Goettsch; Maria Mavilio; Anna Artati; Omero A Paoluzi; Jerzy Adamski; Geltrude Mingrone; Bart Staels; Remy Burcelin; Giovanni Monteleone; Rossella Menghini; Nikolaus Marx; Massimo Federici
Journal:  Mol Metab       Date:  2020-03-13       Impact factor: 7.422

5.  Microbiome and Cardiovascular Disease.

Authors:  Hilde Herrema; Max Nieuwdorp; Albert K Groen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 6.  The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions.

Authors:  Marius Trøseid; Geir Øystein Andersen; Kaspar Broch; Johannes Roksund Hov
Journal:  EBioMedicine       Date:  2020-02-12       Impact factor: 8.143

7.  Association of midlife antibiotic use with subsequent cognitive function in women.

Authors:  Raaj S Mehta; Paul Lochhead; Yiqing Wang; Wenjie Ma; Long H Nguyen; Bharati Kochar; Curtis Huttenhower; Francine Grodstein; Andrew T Chan
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

8.  Estimation of Cardiovascular Disease Risk Factors in the Undefined Participants of Campaign in Isfahan in 2017.

Authors:  Maryam Bemanalizadeh; Ziba Farajzadegan; Parastou Golshiri
Journal:  Int J Prev Med       Date:  2021-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.